Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.

PloS one - 1 Jan 2020

Shire Norah J, Klein Alyssa B, Golozar Asieh, Collins Jenna M, Fraeman Kathy H, Nordstrom Beth L, McEwen Robert, Hembrough Todd, Rizvi Naiyer A

Abstract excerpt

BACKGROUND: Mutations in STK11 (STK11m) and frequently co-occurring KRAS mutations (KRASm/STK11m) are associated with poor survival in metastatic NSCLC (mNSCLC) immuno-oncology trials. There are limited data regarding the prognostic significance of these mutations in a real-world setting. METHODS: This retrospective cohort study analyzed de-identified electronic medical records from the Flatiron Clinico-Genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Protein Serine-Threonine Kinases
Share to AMP-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Neoplasm Metastasis

Share to Progression-Free Survival

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32881920
DOI: 10.1371/journal.pone.0238358
PMCID: PMC7470384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.PMID 32881920Read ↗

A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung CancerSemantic proximity Read ↗

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.Semantic proximity Read ↗

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.Semantic proximity Read ↗

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.Semantic proximity Read ↗

STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.Semantic proximity Read ↗

STK11 genetic alterations in metastatic EGFR mutant lung cancerSemantic proximity Read ↗

Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.Semantic proximity Read ↗

STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.Semantic proximity Read ↗

Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.Semantic proximity Read ↗

Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.Semantic proximity Read ↗

STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.